Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26121068 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAL3MBTL1GAAADRB1 | |
| SCHEMBL17835547 | 0.82 | LMNA (0.48) | LMNAL3MBTL1KDM4ETSHRIDO1 | |
| SCHEMBL25419566 | 0.82 | LMNA (0.48) | LMNAL3MBTL1KDM4ETSHRIDO1 | |
| SCHEMBL29713534 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAL3MBTL1GAAADRB1 | |
| SCHEMBL24933822 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAL3MBTL1GAAADRB1 | |
| SCHEMBL4204504 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAL3MBTL1GAAADRB1 | |
| SCHEMBL30396073 | 0.74 | ALDH1A1 (0.45) | SMN1; SMN2LMNACFTRSLC6A2SLC6A4 | |
| SCHEMBL1579049 | 0.74 | LMNA (0.57) | SMN1; SMN2LMNAL3MBTL1GAAKDM4E | |
| SCHEMBL21009583 | 0.74 | LMNA (0.57) | SMN1; SMN2LMNAL3MBTL1GAAKDM4E | |
| SCHEMBL32346286 | 0.74 | LMNA (0.57) | SMN1; SMN2LMNAL3MBTL1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| CN-117897384-A | CDK2 inhibitors | 缆图药品公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11932648-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230322791-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-10-12 | — | — | US | disclosed |
| US-20230322791-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-10-12 | — | — | US | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2023091726-A1 | INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) | SYROS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932648-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | SMN1; SMN2 2189/4885LMNA 2403/4885L3MBTL1 2771/4885 |
| US-20230322791-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | SMN1; SMN2 2189/4885LMNA 2403/4885L3MBTL1 2771/4885 |
| US-11970498-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | SMN1; SMN2 2189/4885LMNA 2403/4885L3MBTL1 2771/4885 |
| US-20240383902-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | SMN1; SMN2 2189/4885LMNA 2403/4885L3MBTL1 2771/4885 |
| US-20230159535-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | SMN1; SMN2 2189/4885LMNA 2403/4885L3MBTL1 2771/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | SMN1; SMN2 2767/4885LMNA 1435/4885L3MBTL1 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.